JP2009507850A5 - - Google Patents

Download PDF

Info

Publication number
JP2009507850A5
JP2009507850A5 JP2008530186A JP2008530186A JP2009507850A5 JP 2009507850 A5 JP2009507850 A5 JP 2009507850A5 JP 2008530186 A JP2008530186 A JP 2008530186A JP 2008530186 A JP2008530186 A JP 2008530186A JP 2009507850 A5 JP2009507850 A5 JP 2009507850A5
Authority
JP
Japan
Prior art keywords
lecozotan
patient
max
pharmaceutical composition
plasma concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008530186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009507850A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/034813 external-priority patent/WO2007030589A2/en
Publication of JP2009507850A publication Critical patent/JP2009507850A/ja
Publication of JP2009507850A5 publication Critical patent/JP2009507850A5/ja
Withdrawn legal-status Critical Current

Links

JP2008530186A 2005-09-09 2006-09-06 レコゾタンを含む薬学的剤形および組成物 Withdrawn JP2009507850A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71541705P 2005-09-09 2005-09-09
PCT/US2006/034813 WO2007030589A2 (en) 2005-09-09 2006-09-06 Pharmaceutical dosage forms and compositions comprising lecoztan

Publications (2)

Publication Number Publication Date
JP2009507850A JP2009507850A (ja) 2009-02-26
JP2009507850A5 true JP2009507850A5 (enExample) 2009-11-05

Family

ID=37836444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008530186A Withdrawn JP2009507850A (ja) 2005-09-09 2006-09-06 レコゾタンを含む薬学的剤形および組成物

Country Status (17)

Country Link
EP (1) EP1928863A2 (enExample)
JP (1) JP2009507850A (enExample)
KR (1) KR20080043855A (enExample)
CN (1) CN101258146A (enExample)
AR (1) AR058033A1 (enExample)
AU (1) AU2006287543A1 (enExample)
BR (1) BRPI0615771A2 (enExample)
CA (1) CA2620491A1 (enExample)
CR (1) CR9800A (enExample)
EC (1) ECSP088236A (enExample)
GT (1) GT200600403A (enExample)
IL (1) IL189827A0 (enExample)
NO (1) NO20081100L (enExample)
PE (1) PE20070334A1 (enExample)
RU (1) RU2008108216A (enExample)
TW (1) TW200800198A (enExample)
WO (1) WO2007030589A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
WO2007006003A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
CA2759180A1 (en) * 2009-05-13 2010-11-18 Sunovion Pharmaceuticals Inc. Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5049450B2 (ja) * 2000-09-29 2012-10-17 アボツト・ヘルスケア・プロダクツ・ベー・ブイ イオン強度に依存しない徐放性製薬組成物
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
BRPI0609370A2 (pt) * 2005-03-01 2010-03-30 Wyeth Corp cloridrato de 4-ciano-n-{(2r)-2-[4-(2,3-dihidro-benzo[1,4]dioxin-5-il)-pip erazin-1-il]-propil}-n-piridin-2-il-benzamida cristalino e amorfo

Similar Documents

Publication Publication Date Title
JP2025142338A5 (enExample)
ES2433930T3 (es) Composición farmacéutica para administración sublingual
JP2013082720A5 (enExample)
JP2011502997A5 (enExample)
EP4076380B1 (en) Transmucosal therapeutic system containing agomelatine
Behra et al. An exhaustive review on recent advancement in pharmaceutical bioadhesive used for systemic drug delivery through oral mucosa for achieving maximum pharmacological response and effect
CN100594936C (zh) 改善透粘膜给药制剂的吸收的方法
JP2023540149A (ja) 抗ウイルス化合物の製剤
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
JP2021520400A (ja) エダラボン医薬組成物
JP2010538066A5 (enExample)
EP4076381B1 (en) Transmucosal therapeutic system containing agomelatine
JP2006524190A5 (enExample)
ES2652266T3 (es) Composición sólida de dosificación oral de ibuprofeno que comprende un copolímero de ácido metacrílico
KR101697773B1 (ko) 독소필린을 포함하는 변형 방출 조성물
JP2009507850A5 (enExample)
JP2012031164A (ja) フィルム状製剤
PT1646373E (pt) Composição farmacêutica orodispersível de um composto antitrombótico
RU2008108216A (ru) Фармацевтические дозированные формы и составы, содержащие лекозотан
HK40110942A (en) Transmucosal therapeutic system containing agomelatine
ES2548090T3 (es) Uso de una suspensión oral que comprende acetato de megestrol para el tratamiento de asma bronquial
HK40082930A (en) Transmucosal therapeutic system containing agomelatine
HK40082930B (en) Transmucosal therapeutic system containing agomelatine
HK40089892A (zh) 含有阿戈美拉汀的经粘膜治疗系统
RU2015140567A (ru) Фармацевтические композиции на основе донепезила, характеризующиеся специфическим профилем растворимости in vitro или фармакокинетическими параметрами